Mallinckrodt’s stannsoporfin turned away by FDA
US regulators have rejected an application by Mallinckrodt to market stannsoporfin for newborns at risk of jaundice.
Read More
Tag: cenegermin
US approves first drug for neurotrophic keratitis
US regulators have approved the first drug to treat neurotrophic keratitis, a rare degenerative disease affecting the cornea.
Read More
NICE rejects rare eye disease drug
Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
Read More
EU to review first drug for neurotrophic keratitis
European regulators have agreed to review Italian drugmaker Dompe’s orphan drug Oxervate, opening the door to what may potentially become the first biotech treatment available to patients with the more severe forms of an eye condition called neurotrophic keratitis.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
